Methylene Blue: Magic Bullet for Vasoplegia?

Methylene blue (MB) has received much attention in the perioperative and critical care literature because of its ability to antagonize the profound vasodilation seen in distributive (also referred to as vasodilatory or vasoplegic) shock states. This review will discuss the pharmacologic properties of MB and review the critical care, liver transplantation, and cardiac anesthesia literature with respect to the efficacy and safety of MB for the treatment of shock. Although improved blood pressure has consistently been demonstrated with the use of MB in small trials and case reports, better oxygen delivery or decreased mortality with MB use has not been demonstrated. Large randomized controlled trials are still necessary to identify the role of MB in hemodynamic resuscitation of the critically ill.

[1]  P. Evora,et al.  "Methylene blue should be relegated to rescue use and not as first-line therapy" cannot become a paradigm. , 2014, Journal of cardiothoracic and vascular anesthesia.

[2]  A. Zangrillo,et al.  Methylene blue: between scylla (meta-analysis) and charybdis (propensity). , 2014, Journal of Cardiothoracic and Vascular Anesthesia.

[3]  G. Fischer,et al.  Methylene blue: the Trojan horse. , 2014 .

[4]  H. Schäfers,et al.  Vasopressin Induces Rectosigmoidal Mucosal Ischemia During Cardiopulmonary Bypass , 2014, Journal of cardiac surgery.

[5]  Hung-mo Lin,et al.  Methylene blue is associated with poor outcomes in vasoplegic shock. , 2013, Journal of cardiothoracic and vascular anesthesia.

[6]  R. Altman,et al.  PharmGKB summary: methylene blue pathway , 2013, Pharmacogenetics and genomics.

[7]  J. Gutsche,et al.  Clinical update in liver transplantation. , 2013, Journal of cardiothoracic and vascular anesthesia.

[8]  A. Zangrillo,et al.  Methylene blue as a vasopressor: a meta-analysis of randomised trials. , 2013, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[9]  J. Kern,et al.  The role of methylene blue in serotonin syndrome following cardiac transplantation: a case report and review of the literature. , 2012, The Journal of thoracic and cardiovascular surgery.

[10]  P. Evora,et al.  Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview. , 2012, Current drug targets.

[11]  M. Wachs,et al.  The response to methylene blue in patients with severe hypotension during liver transplantation. , 2012, Journal of clinical anesthesia.

[12]  H. Zhang,et al.  Postreperfusion syndrome during orthotopic liver transplantation: a single-center experience. , 2012, Hepatobiliary & pancreatic diseases international : HBPD INT.

[13]  M. J. Rosique,et al.  Effect of methylene blue on the hemodynamic instability resulting from liver ischemia and reperfusion in rabbits. , 2011, Transplantation proceedings.

[14]  E. Pretto,et al.  The effect of methylene blue during orthotopic liver transplantation on post reperfusion syndrome and postoperative graft function , 2011, Journal of hepato-biliary-pancreatic sciences.

[15]  M. Westphal,et al.  Short-term effects of terlipressin bolus infusion on sublingual microcirculatory blood flow during septic shock , 2011, Intensive Care Medicine.

[16]  C. Ince,et al.  Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study , 2010, Critical care.

[17]  P. Asfar,et al.  Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside , 2010, Intensive Care Medicine.

[18]  Z. Kadry,et al.  Vasoplegic shock during liver transplantation: is the preoperative cGMP plasma level a potential predictor of hemodynamic instability? , 2010, Medical Science Monitor.

[19]  G. Fischer,et al.  Methylene blue for vasopressor-resistant vasoplegia syndrome during liver transplantation. , 2010, Journal of cardiothoracic and vascular anesthesia.

[20]  G. Fischer,et al.  Vasoplegia during cardiac surgery: current concepts and management. , 2010, Seminars in thoracic and cardiovascular surgery.

[21]  M. Vervloet,et al.  A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. , 2010, Nitric oxide : biology and chemistry.

[22]  M. Covelo,et al.  Methylene blue used as a bridge to liver transplantation postoperative recovery: a case report. , 2010, Transplantation proceedings.

[23]  Ydriss Añuez Castillo,et al.  Is it possible to distinguish between vasoplegic syndrome and postreperfusion syndrome during liver graft reperfusion? , 2010, Anesthesia and analgesia.

[24]  Gregory W Fischer,et al.  Early On–Cardiopulmonary Bypass Hypotension and Other Factors Associated With Vasoplegic Syndrome , 2009, Circulation.

[25]  Guocai Tao,et al.  Vasoplegic Syndrome During Liver Transplantation , 2009, Anesthesia and analgesia.

[26]  M. Ramsay,et al.  Postreperfusion syndrome during liver transplantation for cirrhosis: Outcome and predictors , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[27]  C. Barja-Fidalgo,et al.  Late, but Not Early, Inhibition of Soluble Guanylate Cyclase Decreases Mortality in a Rat Sepsis Model , 2009, Journal of Pharmacology and Experimental Therapeutics.

[28]  S. Raja,et al.  Should angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists be omitted before cardiac surgery to avoid postoperative vasodilation? , 2008, Interactive cardiovascular and thoracic surgery.

[29]  A. Marcos,et al.  The impact of postreperfusion syndrome on short‐term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[30]  M. Ramsay.  The reperfusion syndrome: Have we made any progress? , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[31]  F. Falter,et al.  Methylene blue for CPB. , 2007, Anesthesia and Analgesia.

[32]  John A. Almeida,et al.  Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome. , 2007, European journal of gastroenterology & hepatology.

[33]  R. Bellomo,et al.  Selecting a vasopressor drug for vasoplegic shock after adult cardiac surgery: a systematic literature review. , 2007, The Annals of thoracic surgery.

[34]  A. Cartell,et al.  Extensive skin necrosis following use of noradrenaline and dopamine , 2006, Journal of the European Academy of Dermatology and Venereology.

[35]  E. Kwok,et al.  Use of Methylene Blue in Sepsis: A Systematic Review , 2006, Journal of intensive care medicine.

[36]  Sang-Bum Hong,et al.  Skin Necrosis after a Low-Dose Vasopressin Infusion through a Central Venous Catheter for Treating Septic Shock , 2006, The Korean journal of internal medicine.

[37]  S. Kaplan,et al.  Methylene Blue Decreases Ischemia-Reperfusion (I/R)-Induced Spinal Cord Injury: An in vivo Study in an I/R Rabbit Model , 2006, European Surgical Research.

[38]  O. V. Evgenov,et al.  NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.

[39]  A. Maslow,et al.  The Hemodynamic Effects of Methylene Blue When Administered at the Onset of Cardiopulmonary Bypass , 2006, Anesthesia and analgesia.

[40]  G. Shanmugam.  Vasoplegic syndrome--the role of methylene blue. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[41]  A. Fotopoulos,et al.  Effects of Nitric Oxide Inhibition by Methylene Blue in Cirrhotic Patients with Ascites , 2005, Digestive Diseases and Sciences.

[42]  B. Millar,et al.  Methylthioninium chloride: pharmacology and clinical applications with special emphasis on nitric oxide mediated vasodilatory shock during cardiopulmonary bypass , 2005, Anaesthesia.

[43]  C. Piccinato,et al.  THE USE OF METHYLENE BLUE IN THE TREATMENT OF ANAPHYLACTIC SHOCK INDUCED BY COMPOUND 48/80: EXPERIMENTAL STUDIES IN RABBITS , 2005, Shock.

[44]  U. Demirkılıç,et al.  Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. , 2005, The Annals of thoracic surgery.

[45]  B. Koneru,et al.  Vasopressor administration during liver transplant surgery and its effect on endotracheal reintubation rate in the postoperative period: a prospective, randomized, double-blind, placebo-controlled trial. , 2005, Clinical therapeutics.

[46]  P. Evora,et al.  Methylene blue as drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass. , 2004, The Journal of thoracic and cardiovascular surgery.

[47]  T. Mihaljevic,et al.  Risk factors and outcomes for 'vasoplegia syndrome' following cardiac transplantation. , 2004, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[48]  R. Levin,et al.  Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. , 2004, The Annals of thoracic surgery.

[49]  J. Bakker,et al.  Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock* , 2004, Critical care medicine.

[50]  M. Dünser,et al.  Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors* , 2003, Critical care medicine.

[51]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[52]  M. Grayling,et al.  Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis. , 2003, The Journal of thoracic and cardiovascular surgery.

[53]  M. Yuksel,et al.  The Influence of Methylene Blue Infusion on Cytokine Levels during Severe Sepsis , 2002, Anaesthesia and intensive care.

[54]  J. Preiser,et al.  Does methylene blue administration to septic shock patients affect vascular permeability and blood volume? , 2002, Critical care medicine.

[55]  M. Bellamy,et al.  The Effect of Methylene Blue on the Hemodynamic Changes During Ischemia Reperfusion Injury in Orthotopic Liver Transplantation , 2002, Anesthesia and analgesia.

[56]  A. Nanashima,et al.  Analysis of postrevascularization syndrome after orthotopic liver transplantation: the experience of an Australian liver transplantation center. , 2001, Journal of hepato-biliary-pancreatic surgery.

[57]  O. V. Evgenov,et al.  Infusion of methylene blue in human septic shock: A pilot, randomized, controlled study , 2001, Critical care medicine.

[58]  A. Haverich,et al.  Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. , 2001, The Journal of thoracic and cardiovascular surgery.

[59]  C. Madl,et al.  Methylene Blue Improves the Hepatopulmonary Syndrome , 2001, Annals of Internal Medicine.

[60]  R. Moreau,et al.  Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. , 2001, American journal of respiratory and critical care medicine.

[61]  D. Landry,et al.  The pathogenesis of vasodilatory shock. , 2001, The New England journal of medicine.

[62]  D. Loisance,et al.  Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. , 2001, The Annals of thoracic surgery.

[63]  A. Lomniczi,et al.  Methylene Blue Inhibits the Increase of Inducible Nitric Oxide Synthase Activity Induced by Stress and Lipopolysaccharide in the Medial Basal Hypothalamus of Rats , 2000, Neuroimmunomodulation.

[64]  T. Carrel,et al.  Low Systemic Vascular Resistance After Cardiopulmonary Bypass: Incidence, Etiology, and Clinical Importance , 2000, Journal of cardiac surgery.

[65]  B. Lauterburg,et al.  Pharmacokinetics and organ distribution of intravenous and oral methylene blue , 2000, European Journal of Clinical Pharmacology.

[66]  Yiu.  Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock? , 2000, The Journal of thoracic and cardiovascular surgery.

[67]  T. Lincoln,et al.  Regulation of myosin phosphatase by a specific interaction with cGMP- dependent protein kinase Ialpha. , 1999, Science.

[68]  P. Parrilla,et al.  Need for inotropic and/or vasopressor drugs during liver transplantation. , 1999, Transplantation proceedings.

[69]  J. Vincent,et al.  An open-label dose escalation study of the nitric oxide synthase inhibitor, NG-methyl-L-arginine hydrochloride (546C88), in patients with septic shock , 1999 .

[70]  G. Kojda,et al.  Regulation of basal myocardial function by NO. , 1999, Cardiovascular research.

[71]  M. Oz,et al.  Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. , 1998, The Journal of thoracic and cardiovascular surgery.

[72]  G. Hernández,et al.  Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. , 1998, Journal of critical care.

[73]  E. Buffolo,et al.  Vasoplegic syndrome after open heart surgery. , 1998, The Journal of cardiovascular surgery.

[74]  C. Holt,et al.  Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. , 1998, Journal of molecular and cellular cardiology.

[75]  P. Myles,et al.  Endogenous nitric oxide and low systemic vascular resistance after cardiopulmonary bypass. , 1997, Journal of cardiothoracic and vascular anesthesia.

[76]  M. Fallon,et al.  The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. , 1997, Gastroenterology.

[77]  C. Visser,et al.  Left ventricular systolic and diastolic function in septic shock , 1997, Intensive Care Medicine.

[78]  P. Evora,et al.  Methylene blue administration in SIRS after cardiac operations. , 1997, The Annals of thoracic surgery.

[79]  T. Evans,et al.  Nitric oxide, the biological mediator of the decade: fact or fiction? , 1997, The European respiratory journal.

[80]  D. Traber,et al.  Nitric oxide inhibition in the treatment of septic shock. , 1996, Critical care medicine.

[81]  P. McGinn.  Reversal of the haemodynamic features of acute liver failure by methylene blue , 1996, Intensive Care Medicine.

[82]  A Haverich,et al.  Systemic inflammatory response syndrome after cardiac operations. , 1996, The Annals of thoracic surgery.

[83]  E. Masini,et al.  Increased production of nitric oxide by neutrophils and monocytes from cirrhotic patients with ascites and hyperdynamic circulation , 1995, Hepatology.

[84]  J. Vincent,et al.  Methylene blue administration in septic shock: a clinical trial. , 1995, Critical care medicine.

[85]  A. Groeneveld,et al.  Methylene blue increases myocardial function in septic shock. , 1995, Critical care medicine.

[86]  J. Mcmillan,et al.  Methylene blue fails to improve hypoxaemia post orthotopic liver transplantation (OLT) , 1995, Australian and New Zealand Journal of Medicine.

[87]  O. Griffith,et al.  NG‐methyl‐L‐arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs , 1994, Critical care medicine.

[88]  C. Bucca,et al.  Methylene blue in the hepatopulmonary syndrome. , 1994, The New England journal of medicine.

[89]  J. Cunningham,et al.  Nitric oxide inhibition in the treatment of the sepsis syndrome is detrimental to tissue oxygenation. , 1994, The Journal of surgical research.

[90]  J. Stamler,et al.  Methylene blue reverses endotoxin-induced hypotension. , 1994, Circulation research.

[91]  E. Buffolo,et al.  Vasoplegic syndrome: a new dilemma. , 1994, The Journal of thoracic and cardiovascular surgery.

[92]  J. Cohen,et al.  Evidence of increased nitric oxide production in patients with the sepsis syndrome. , 1993, Circulatory shock.

[93]  R. Palmer.  The discovery of nitric oxide in the vessel wall. A unifying concept in the pathogenesis of sepsis. , 1993, Archives of surgery.

[94]  B. Mayer,et al.  Inhibition of nitric oxide synthesis by methylene blue. , 1993, Biochemical pharmacology.

[95]  C. Natanson,et al.  N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin , 1992, The Journal of experimental medicine.

[96]  Harald H.H.W. Schmidt.  NO•, CO and •OH Endogenous soluble guanylyl cyclase‐activating factors , 1992, FEBS letters.

[97]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[98]  C. Nathan,et al.  N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine. , 1991, The Journal of biological chemistry.

[99]  R. Busse,et al.  Induction of nitric oxide synthase by cytokines in vascular smooth muscle cells , 1990, FEBS letters.

[100]  J. Adams,et al.  Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis. , 1990, Biochemical and biophysical research communications.

[101]  J. Adams,et al.  hypotension: Implications for the involvement of nitric oxide , 2022 .

[102]  M. Pinsky,et al.  Postreperfusion syndrome: cardiovascular collapse following hepatic reperfusion during liver transplantation. , 1987, Transplantation proceedings.

[103]  P. Poppers,et al.  Spurious pulse oximeter desaturation with methylene blue injection. , 1986, Anesthesiology.

[104]  S Westaby,et al.  Complement and the damaging effects of cardiopulmonary bypass. , 1983, Thorax.

[105]  L. Ignarro,et al.  Purification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IX. , 1982, Archives of biochemistry and biophysics.

[106]  L. Ignarro,et al.  Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite. , 1981, Canadian journal of physiology and pharmacology.

[107]  O. Huet,et al.  Septic shock: desperately seeking treatment. , 2014, Clinical science.

[108]  B. Ng,et al.  The role of methylene blue in serotonin syndrome: a systematic review. , 2010, Psychosomatics.

[109]  C. Hinds,et al.  Symmetrical peripheral gangrene: association with noradrenaline administration , 2005, Intensive Care Medicine.

[110]  J. Sinex.  Pulse oximetry: principles and limitations. , 1999, The American journal of emergency medicine.

[111]  J. Vincent,et al.  An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. , 1999, Critical care medicine.

[112]  C. Thiemermann,et al.  NO in Septic Shock , 1997 .

[113]  G. Hill.  The Inflammatory Response to Cardiopulmonary Bypass , 1996, International anesthesiology clinics.

[114]  D. Beasley,et al.  Interleukin 1 activates soluble guanylate cyclase in human vascular smooth muscle cells through a novel nitric oxide-independent pathway. , 1994, The Journal of experimental medicine.

[115]  S. Snyder,et al.  Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. , 1990, Proceedings of the National Academy of Sciences of the United States of America.